3 Promising Penny Stocks With Market Caps Over $1B

In This Article:

As the U.S. stock market experiences a rollercoaster ride, with major indices seeing both surges and declines amid economic uncertainties, investors are increasingly looking for opportunities that promise growth potential without excessive risk. Penny stocks, though an old term, continue to represent an intriguing investment area by highlighting smaller or less-established companies that could offer significant value at lower price points. By focusing on those with strong financials and clear growth paths, investors can potentially uncover hidden gems among these stocks.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.83947

$6.1M

★★★★★★

Sensus Healthcare (NasdaqCM:SRTS)

$4.65

$76.7M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$141.07M

★★★★★★

Safe Bulkers (NYSE:SB)

$3.80

$398.41M

★★★★☆☆

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.46

$74.62M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.51

$49.83M

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$0.85

$76.45M

★★★★★☆

TETRA Technologies (NYSE:TTI)

$3.35

$443.52M

★★★★☆☆

Smith Micro Software (NasdaqCM:SMSI)

$0.7455

$13.25M

★★★★☆☆

Click here to see the full list of 770 stocks from our US Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Clover Health Investments

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Clover Health Investments, Corp. offers Medicare Advantage plans in the United States and has a market cap of approximately $1.87 billion.

Operations: Clover Health generates revenue primarily from its Insurance segment, totaling approximately $1.37 billion.

Market Cap: $1.87B

Clover Health Investments, Corp. has faced challenges with profitability, reporting a net loss of US$22.09 million for Q4 2024, though this marks an improvement from the previous year's larger loss. The company is not expected to achieve profitability in the next three years but maintains a strong cash position with a runway exceeding three years due to positive free cash flow. Revenue growth is anticipated at 14.64% annually, supported by guidance projecting insurance revenue between US$1.8 billion and US$1.875 billion for 2025. Despite trading at 62% below estimated fair value, Clover remains debt-free with stable weekly volatility and experienced management and board teams.